Barclays’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-60,000
| Closed | -$8.26M | – | 5411 |
|
|
2024
Q2 | $8.26M | Buy |
+60,000
| New | +$8.23M | ﹤0.01% | 1275 |
|
|
2020
Q4 | – | Sell |
-1,400
| Closed | -$135K | – | 5093 |
|
|
2020
Q3 | $135K | Hold |
1,400
| – | – | ﹤0.01% | 4076 |
|
|
2020
Q2 | $171K | Sell |
1,400
-20,200
| -94% | -$2.23M | ﹤0.01% | 4183 |
|
|
2020
Q1 | $1.87M | Sell |
21,600
-88,000
| -80% | -$8.61M | ﹤0.01% | 2356 |
|
|
2019
Q4 | $11.8M | Buy |
109,600
+94,300
| +616% | +$9.87M | 0.01% | 1273 |
|
|
2019
Q3 | $1.38M | Buy |
15,300
+1,000
| +7% | +$93.4K | ﹤0.01% | 3324 |
|
|
2019
Q2 | $1.21M | Hold |
14,300
| – | – | ﹤0.01% | 3490 |
|
|
2019
Q1 | $1.26M | Buy |
14,300
+5,700
| +66% | +$476K | ﹤0.01% | 3143 |
|
|
2018
Q4 | $614K | Sell |
8,600
-44,300
| -84% | -$4.24M | ﹤0.01% | 3614 |
|
|
2018
Q3 | $6.5M | Buy |
52,900
+4,200
| +9% | +$477K | ﹤0.01% | 1563 |
|
|
2018
Q2 | $4.78M | Sell |
48,700
-5,600
| -10% | -$501K | ﹤0.01% | 1759 |
|
|
2018
Q1 | $4.5M | Buy |
54,300
+13,900
| +34% | +$1.17M | ﹤0.01% | 1718 |
|
|
2017
Q4 | $3.13M | Sell |
40,400
-1,400
| -3% | -$95.5K | ﹤0.01% | 2024 |
|
|
2017
Q3 | $2.56M | Sell |
41,800
-43,700
| -51% | -$2.31M | ﹤0.01% | 2109 |
|
|
2017
Q2 | $3.93M | Buy |
85,500
+84,400
| +7,673% | +$4.09M | ﹤0.01% | 1645 |
|
|
2017
Q1 | $48K | Sell |
1,100
-149,200
| -99% | -$6.39M | ﹤0.01% | 5357 |
|
|
2016
Q4 | $5.82M | Buy |
150,300
+139,600
| +1,305% | +$6.32M | 0.01% | 1298 |
|
|
2016
Q3 | $542K | Sell |
10,700
-180,300
| -94% | -$8.98M | ﹤0.01% | 3151 |
|
|
2016
Q2 | $8.68M | Buy |
191,000
+182,300
| +2,095% | +$8.39M | 0.01% | 916 |
|
|
2016
Q1 | $339K | Sell |
8,700
-40,400
| -82% | -$1.6M | ﹤0.01% | 3456 |
|
|
2015
Q4 | $2.75M | Sell |
49,100
-30,700
| -38% | -$1.56M | ﹤0.01% | 1771 |
|
|
2015
Q3 | $3.11M | Sell |
79,800
-113,200
| -59% | -$5.47M | ﹤0.01% | 1740 |
|
|
2015
Q2 | $9.07M | Buy |
193,000
+21,300
| +12% | +$903K | 0.01% | 1095 |
|
|
2015
Q1 | $6.7M | Buy |
171,700
+143,800
| +515% | +$5.14M | 0.01% | 1340 |
|
|
2014
Q4 | $614K | Sell |
27,900
-14,100
| -34% | -$267K | ﹤0.01% | 3663 |
|
|
2014
Q3 | $630K | Buy |
42,000
+2,400
| +6% | +$35.9K | ﹤0.01% | 3762 |
|
|
2014
Q2 | $554K | Buy |
39,600
+11,200
| +39% | +$158K | ﹤0.01% | 3875 |
|
|
2014
Q1 | $454K | Sell |
28,400
-161,800
| -85% | -$2.77M | ﹤0.01% | 4051 |
|
|
2013
Q4 | $1.71M | Sell |
190,200
-62,300
| -25% | -$608K | ﹤0.01% | 2834 |
|
|
2013
Q3 | $2.78M | Buy |
252,500
+166,400
| +193% | +$2.29M | ﹤0.01% | 2220 |
|
|
2013
Q2 | $1.15M | Buy |
+86,100
| New | +$1.06M | ﹤0.01% | 3184 |
|
Other funds holding NBIX
VPM
VCM
Barclays's NBIX Position: Q1 2026 in Review
Barclays reduced its Neurocrine Biosciences (NBIX) stake by 3.3% in Q1 2026, selling an estimated $1.1M and leaving 243,984 shares worth $32.1M. The position accounts for 0.01% of the portfolio, ranked #896.
Barclays first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.7M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Barclays held 243,984 shares of Neurocrine Biosciences worth $32.1M as of Q1 2026.
- Barclays sold 8,257 Neurocrine Biosciences shares in Q1 2026, an estimated $1.1M.
- Neurocrine Biosciences made up 0.01% of Barclays's portfolio in Q1 2026, its #896 holding.
- Barclays first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Neurocrine Biosciences position peaked at $42.7M in Q3 2025.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.